FDA Grants Accelerated Approval to Sotorasib for NSCLC

On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.

Read the FDA announcement.

Read the Amgen announcement.

Posted 6/1/2021